Background The impact of COVID-19 in hypertrophic cardiomyopathy (HCM), particularly in the post-vaccine era, remains ...
Severe COVID-19 is defined as SARS-CoV-2 infection with hypoxemia, respiratory distress (respiratory rate >30), and/or severe pneumonia on imaging (>50% infiltrates). 46, 47 Patients with ...
Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy ...
Ziyad Al-Aly is chief of research and development at VA St. Louis Health Care System and a clinical epidemiologist at Washington University in St. Louis. From the very early days of the pandemic, ...
After the U.S. Food and Drug Administration (FDA) approved the emergency use of the 2024-2025 COVID-19 vaccines many questions are beginning to circulate. In the FDA's press release on Aug. 22, the ...
Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results